Moreover, in the EUSTAR cohort, patients with ILD and anti-PM/Scl (an autoantibody that is associated with scleromyositis as detailed below), vital capacity tended to improve whereas diffusion capacity of lung for carbon monoxide remained stable at one-year follow-up (91). The gene discussed is PRB1; the disease is interstitial lung disease.